Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytek Biosciences (CTKB) Research & Development (2020 - 2025)

Cytek Biosciences' Research & Development history spans 6 years, with the latest figure at $9.0 million for Q4 2025.

  • For Q4 2025, Research & Development fell 7.83% year-over-year to $9.0 million; the TTM value through Dec 2025 reached $36.5 million, down 7.44%, while the annual FY2025 figure was $36.5 million, 7.45% down from the prior year.
  • Research & Development reached $9.0 million in Q4 2025 per CTKB's latest filing, roughly flat from $9.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $12.1 million in Q2 2023 to a low of $5.1 million in Q1 2021.
  • Average Research & Development over 5 years is $9.0 million, with a median of $9.3 million recorded in 2024.
  • Peak YoY movement for Research & Development: skyrocketed 112.41% in 2021, then fell 17.59% in 2024.
  • A 5-year view of Research & Development shows it stood at $7.1 million in 2021, then surged by 37.75% to $9.7 million in 2022, then rose by 11.51% to $10.9 million in 2023, then decreased by 10.54% to $9.7 million in 2024, then fell by 7.83% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Research & Development are $9.0 million (Q4 2025), $9.0 million (Q3 2025), and $8.8 million (Q2 2025).